MNKA Stock Overview
Artemis Therapeutics Inc., a beauty company, engages in the development and distribution of skincare products in Israel.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Manuka, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.04 |
| 52 Week High | US$1.89 |
| 52 Week Low | US$0.01 |
| Beta | 0 |
| 1 Month Change | -20.00% |
| 3 Month Change | n/a |
| 1 Year Change | -86.58% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -98.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| MNKA | US Personal Products | US Market | |
|---|---|---|---|
| 7D | 0% | -3.3% | 0.3% |
| 1Y | -86.6% | -24.1% | 24.2% |
Return vs Industry: MNKA underperformed the US Personal Products industry which returned -24.1% over the past year.
Return vs Market: MNKA underperformed the US Market which returned 24.2% over the past year.
Price Volatility
| MNKA volatility | |
|---|---|
| MNKA Average Weekly Movement | n/a |
| Personal Products Industry Average Movement | 8.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MNKA's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine MNKA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 4 | Shimon Citron | bmanuka.co.il |
Artemis Therapeutics Inc., a beauty company, engages in the development and distribution of skincare products in Israel. The company offers face serum with manuka honey and bee venom, face serum with vitamin C, day cream, nourishing night cream with manuka honey and nee venom, eye cream with manuka honey and bee venom, and face cleanser gel. It also distributes manuka honey imported from New Zealand.
Manuka, Inc. Fundamentals Summary
| MNKA fundamental statistics | |
|---|---|
| Market cap | US$4.48m |
| Earnings (TTM) | -US$1.14m |
| Revenue (TTM) | US$672.00k |
6.7x
P/S Ratio-3.9x
P/E RatioIs MNKA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MNKA income statement (TTM) | |
|---|---|
| Revenue | US$672.00k |
| Cost of Revenue | US$80.00k |
| Gross Profit | US$592.00k |
| Other Expenses | US$1.73m |
| Earnings | -US$1.14m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.01 |
| Gross Margin | 88.10% |
| Net Profit Margin | -169.79% |
| Debt/Equity Ratio | -41.5% |
How did MNKA perform over the long term?
See historical performance and comparison